---
document_datetime: 2023-12-07 15:56:13
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ivozall-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: ivozall-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5432466
conversion_datetime: 2025-12-22 11:19:52.372706
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal | 06/03/2023                                  |                                             | SmPC and PL                      | To update section 4.6 of the SmPC to align to reference product to include the recommendations on the duration of contraception following the end of treatment with a genotoxic drug' and available data. Package leaflet has been updated accordingly. Furthermore, the MAH included changes for the local representative for Lithuania. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Ivozall Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| N/0005            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                 | 03/11/2021   | 02/12/2021    | PL                     | authorised                                               |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|------------------------|----------------------------------------------------------|
| PSUSA/805/2 02012 | Periodic Safety Update EU Single assessment - clofarabine                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/07/2021   | n/a           |                        | PRAC Recommendation - maintenance                        |
| IAIN/0002/G       | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                     | 11/12/2020   | 02/12/2021 no | Annex II and PL longer |                                                          |
| IA/0003/G         | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure Medicinal product | 10/12/2020   | n/a           |                        |                                                          |
| PSUSA/805/2       | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/07/2020   | 17/09/2020    | SmPC and PL            | Refer to Scientific conclusions and grounds recommending |

<div style=\"page-break-after: always\"></div>

<!-- image -->